StreetAlpha
13F holdings · Q3 2026

Novo Holdings A/s

Hellerup, G7 · files as Novo Holdings A/s
Know the moment Novo Holdings A/s filesYou follow Novo Holdings A/s An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1388325

Novo Holdings A/s reported 27 stocks worth $1.5B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are EWTX (14.6%), ASML (11.6%) and BN (10.9%). Compared with Q2 2026, the fund opened new positions in OBX, SRRK and CTNM, added to BN, INSM and XENE and trimmed AVLN, FDMT and PCVX.

Latest filing: what Novo Holdings A/s did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
3 new5 added9 trimmed1 sold outBought about $143M · sold about $125M
New 3
Added 5
Trimmed 9
See all 9 →
Sold out 1
  • Crinetics Pharmace$49.4M

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.5B−13.5% vs last quarter
Stocks held273 new · 1 sold out
Top 5 weight52.3%fairly concentrated
Turnover18%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
EWTX
Edgewise Therapeutics Inc
$217M14.6%5.3MNo change8 of 8
2
ASML
Asml Holding N V
$172M11.6%95KNo change8 of 8
3
BN
Brookfield Corp Fclass A
$163M10.9%4.5M+969K (+28%)8 of 8
4
COAG
Hemab Therapeutics Hldgs Inc
$129M8.7%4.2MNo change2 of 8
5
AVLN
Avalyn Pharma Inc
$98.3M6.6%3.4M−434K (−11%)2 of 8
6
MIRM
Mirum Pharmaceuticals Inc
$96.2M6.5%1.1MNo change8 of 8
7
CRM
Salesforce Inc
$90.3M6.1%393KNo change8 of 8
8
ELVN
Enliven Therapeutics Inc
$45.8M3.1%1MNo change6 of 8
9
FDMT
4D Molecular Therapeutics in
$42.9M2.9%3M−249K (−8%)8 of 8
10
OBX
Obsidian Therapeutics Inc
$42.9M2.9%3.1MNew position1 of 8
🔒 17 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
CRINETICS PHARMACEUTICALS IN
$49.4M1.3M

Reported value

last 8 quarters
$1.7BQ4 '24
$1.3BQ1 '25
$1.4BQ2 '25
$1.6BQ3 '25
$1.3BQ4 '25
$1.2BQ1 '26
$1.7BQ2 '26
$1.5BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Novo Holdings A/s 13F FAQ

What does Novo Holdings A/s own?

Novo Holdings A/s reported 27 stocks worth $1.5B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are EWTX (14.6%), ASML (11.6%) and BN (10.9%). The table above lists every position in the filing (the top 10 without an account).

What did Novo Holdings A/s buy and sell in Q3 2026?

Compared with Q2 2026: 3 new positions, 5 added to, 9 trimmed and 1 sold out. New positions include OBX, SRRK and CTNM.

When will Novo Holdings A/s file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Novo Holdings A/s's portfolio worth?

The Q3 2026 filing reports $1.5B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.